The Form 4 filing, an SEC report of insider stock trades, was filed on Nov. 13, 2026. The sales took place two days earlier, on Nov. 11.
Alan Ezekowitz is a director of Septerna, Inc. (SEPN), which is in the healthcare sector and biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-11 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 7 |
| Shares Transacted | 81,820 |
| Price | $48.09 |
| Total Transaction Value | $3,934,363.25 |
| Insider | |
| Ticker Symbol | SEPN |
| Company | Septerna, Inc. |
| Insider Name | Ezekowitz Alan |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 35,600 |
| Position Size Change | 69.68% |
| Filing | |
| Filing Date | 2026-11-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales reported under transaction code S. The filing covers seven transactions by Alan Ezekowitz.
What was the average price of the transaction?
The average price was $48.09 per share across the seven sales. Prices for each separate sale are not available in the transaction details.
How did this transaction affect the insider's holdings?
He sold 81,820 shares and reported 35,600 shares owned afterward. The shares sold made up 69.68% of his reported holdings before the sales.
What's the total transaction value?
The seven sales totaled $3,934,363.25 when rounded to cents. The value before rounding was $3,934,363.253.
Are there any special circumstances around this transaction?
A Rule 10b5-1 trading-plan reference was identified. These plans set trading instructions in advance. The related footnote text is unavailable, so it is unclear which of the seven sales the reference covers. The plan's start date and schedule are also unknown. The reference alone does not confirm that the plan met the rule's legal requirements or explain the reason for selling.
For research purposes only; not investment advice.